Neurology:房颤影响脑卒中患者长期生存率

2014-02-24 佚名 不详

房颤是一种日益普遍的疾病,它通过增加缺血性卒中的风险而使致死致残率显著升高。卒中伴房颤的患者同不伴房颤的患者相比,神经缺陷更严重,短期30天的死亡率更高。但目前关于其对长期生存影响的研究很少。因此来自加利福尼亚大学医学系Margaret C. Fang博士等研究房颤对卒中长期生存率影响,结果在线发表在2014年2月14日的Neurology杂志上。 研究随访了13,5

房颤是一种日益普遍的疾病,它通过增加缺血性卒中的风险而使致死致残率显著升高。卒中伴房颤的患者同不伴房颤的患者相比,神经缺陷更严重,短期30天的死亡率更高。但目前关于其对长期生存影响的研究很少。因此来自加利福尼亚大学医学系Margaret C. Fang博士等研究房颤对卒中长期生存率影响,结果在线发表在2014年2月14日的Neurology杂志上。

研究随访了13,559例中位时间6年的房颤患者,通过数据库识别卒中患者,共1,025例患者在随访期间发生卒中。通过记录评估卒中严重程度。使用比例风险模型比较在调整华法林使用后,房颤对卒中及非卒中患者生存率的影响,及出院时的残疾程度对生存率的影响。

卒中后中位生存期为1.8年,而与其匹配的非卒中组为5.7年。即使提高限制,分析卒中后存活6个月以上的576例卒中患者,房颤相关卒中的全因死亡风险依然增加。

另外死亡风险和卒中严重程度密切相关,同配对的非卒中患者相比,卒中后重大残疾(丧失独立生活能力)的死亡风险比为2.9,卒中后严重残疾(全瘫)的死亡风险比为8.3。

缺血性卒中伴房颤的患者死亡率增加近三倍。更重要的是卒中对生存率的负面影响并不只是短期事件,用30天死亡率作为卒中对存活影响只是保守估计。该研究额外量化了房颤伴卒中患者对健康的负面影响,并进一步提示通过选择抗凝剂预防卒中及减少严重卒中的重要性。

原始出处:

Fang MC1, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE.Long-term survival after ischemic stroke in patients with atrial fibrillation.Neurology. 2014 Feb 14. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1720014, encodeId=023c1e20014fc, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Mar 24 10:22:00 CST 2014, time=2014-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679051, encodeId=c57d16e90518b, content=<a href='/topic/show?id=7a2684e600b' target=_blank style='color:#2F92EE;'>#脑卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84760, encryptionId=7a2684e600b, topicName=脑卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091e27733095, createdName=weihongyv, createdTime=Mon Jan 26 08:22:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256482, encodeId=4a2d125648217, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Feb 26 00:22:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494972, encodeId=93d014949e20c, content=<a href='/topic/show?id=449c9e02334' target=_blank style='color:#2F92EE;'>#长期生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97023, encryptionId=449c9e02334, topicName=长期生存率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5849143329, createdName=w363522452, createdTime=Wed Feb 26 00:22:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618289, encodeId=f7641618289ce, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Wed Feb 26 00:22:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999377, encodeId=030c19993e7ef, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Mar 27 07:22:00 CST 2014, time=2014-03-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1720014, encodeId=023c1e20014fc, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Mar 24 10:22:00 CST 2014, time=2014-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679051, encodeId=c57d16e90518b, content=<a href='/topic/show?id=7a2684e600b' target=_blank style='color:#2F92EE;'>#脑卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84760, encryptionId=7a2684e600b, topicName=脑卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091e27733095, createdName=weihongyv, createdTime=Mon Jan 26 08:22:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256482, encodeId=4a2d125648217, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Feb 26 00:22:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494972, encodeId=93d014949e20c, content=<a href='/topic/show?id=449c9e02334' target=_blank style='color:#2F92EE;'>#长期生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97023, encryptionId=449c9e02334, topicName=长期生存率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5849143329, createdName=w363522452, createdTime=Wed Feb 26 00:22:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618289, encodeId=f7641618289ce, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Wed Feb 26 00:22:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999377, encodeId=030c19993e7ef, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Mar 27 07:22:00 CST 2014, time=2014-03-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1720014, encodeId=023c1e20014fc, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Mar 24 10:22:00 CST 2014, time=2014-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679051, encodeId=c57d16e90518b, content=<a href='/topic/show?id=7a2684e600b' target=_blank style='color:#2F92EE;'>#脑卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84760, encryptionId=7a2684e600b, topicName=脑卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091e27733095, createdName=weihongyv, createdTime=Mon Jan 26 08:22:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256482, encodeId=4a2d125648217, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Feb 26 00:22:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494972, encodeId=93d014949e20c, content=<a href='/topic/show?id=449c9e02334' target=_blank style='color:#2F92EE;'>#长期生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97023, encryptionId=449c9e02334, topicName=长期生存率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5849143329, createdName=w363522452, createdTime=Wed Feb 26 00:22:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618289, encodeId=f7641618289ce, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Wed Feb 26 00:22:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999377, encodeId=030c19993e7ef, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Mar 27 07:22:00 CST 2014, time=2014-03-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1720014, encodeId=023c1e20014fc, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Mar 24 10:22:00 CST 2014, time=2014-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679051, encodeId=c57d16e90518b, content=<a href='/topic/show?id=7a2684e600b' target=_blank style='color:#2F92EE;'>#脑卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84760, encryptionId=7a2684e600b, topicName=脑卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091e27733095, createdName=weihongyv, createdTime=Mon Jan 26 08:22:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256482, encodeId=4a2d125648217, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Feb 26 00:22:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494972, encodeId=93d014949e20c, content=<a href='/topic/show?id=449c9e02334' target=_blank style='color:#2F92EE;'>#长期生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97023, encryptionId=449c9e02334, topicName=长期生存率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5849143329, createdName=w363522452, createdTime=Wed Feb 26 00:22:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618289, encodeId=f7641618289ce, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Wed Feb 26 00:22:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999377, encodeId=030c19993e7ef, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Mar 27 07:22:00 CST 2014, time=2014-03-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1720014, encodeId=023c1e20014fc, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Mar 24 10:22:00 CST 2014, time=2014-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679051, encodeId=c57d16e90518b, content=<a href='/topic/show?id=7a2684e600b' target=_blank style='color:#2F92EE;'>#脑卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84760, encryptionId=7a2684e600b, topicName=脑卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091e27733095, createdName=weihongyv, createdTime=Mon Jan 26 08:22:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256482, encodeId=4a2d125648217, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Feb 26 00:22:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494972, encodeId=93d014949e20c, content=<a href='/topic/show?id=449c9e02334' target=_blank style='color:#2F92EE;'>#长期生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97023, encryptionId=449c9e02334, topicName=长期生存率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5849143329, createdName=w363522452, createdTime=Wed Feb 26 00:22:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618289, encodeId=f7641618289ce, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Wed Feb 26 00:22:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999377, encodeId=030c19993e7ef, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Mar 27 07:22:00 CST 2014, time=2014-03-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1720014, encodeId=023c1e20014fc, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Mar 24 10:22:00 CST 2014, time=2014-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679051, encodeId=c57d16e90518b, content=<a href='/topic/show?id=7a2684e600b' target=_blank style='color:#2F92EE;'>#脑卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84760, encryptionId=7a2684e600b, topicName=脑卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091e27733095, createdName=weihongyv, createdTime=Mon Jan 26 08:22:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256482, encodeId=4a2d125648217, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Feb 26 00:22:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494972, encodeId=93d014949e20c, content=<a href='/topic/show?id=449c9e02334' target=_blank style='color:#2F92EE;'>#长期生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97023, encryptionId=449c9e02334, topicName=长期生存率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5849143329, createdName=w363522452, createdTime=Wed Feb 26 00:22:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618289, encodeId=f7641618289ce, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Wed Feb 26 00:22:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999377, encodeId=030c19993e7ef, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Mar 27 07:22:00 CST 2014, time=2014-03-27, status=1, ipAttribution=)]
    2014-03-27 yinhl1978

相关资讯

Eur Heart J:房颤患者应用华法林或需过渡策略

一项来自加拿大的回顾性病例对照研究显示,房颤患者在接受华法林抗凝治疗后,第一个月内缺血性卒中风险反而升高,但此后卒中风险逐渐降低至基线水平以下。(Eur Heart J. 2013年12与18日在线版)据研究者介绍,在着名的ROCKET AF和ARISTOTLE研究中,接受新型口服抗凝剂利伐沙班或阿哌沙班治疗的房颤患者在过渡至华法林治疗后,卒中风险也升高。主要研究者Laurent Azoulay认

Neurology:左心耳封堵对有房颤及脑出血患者安全可行

研究要点: 1、有心房颤动及脑出血病史的患者抗凝存在矛盾性。 2、经皮左心耳封堵术对心房颤动及脑出血病史患者安全可行。 为了评价有心房颤动及脑出血病史的患者使用经皮左心耳封堵术的安全性和可行性,德国海德堡大学Veltkamp教授等进行了一项前瞻性研究,相关结论发表在1月14日出版的Neurology杂志上。【原文下载】 研究使用Amplatzer心脏设备对有

Circulation:房颤患者需延长院外抗凝治疗

抗凝对于房颤治疗意义重大,也是防治中风的关键措施,华法林是临床常用抗凝药物。近期,美国奎斯特诊断研究室Dlott博士等首次对房颤患者的院外常规抗凝治疗进行了评估,其研究结果发表于Circulation杂志。 研究者从奎斯特诊断数据库筛选出138319名房颤患者的病例资料,共2683674个国际标准化比值(International Normalized Ratio,I

Circulation:全球房颤数据差异惊人

2014年1月24日,Circulation杂志在线发表了RE-LY房颤注册研究结果,来自46个国家急诊室的心房颤动患者在危险因素和治疗方面的差异十分显著。【原文下载】论文的主要作者、瑞典乌普萨拉大学的Jonas Oldgren博士说,RE-LY AF研究显示,通过对全球随机临床试验和基于北美和西欧社区的研究的比较发现,房颤具有完全不同的年龄、危险因素和并发症模式。这项研究